{"product_id":"blombacks-essential-guide-to-blood-coagulation-isbn-9781394223121","title":"Blombäck's Essential Guide to Blood Coagulation","description":"\u003cp\u003e\u003cb\u003eNew edition of a concise, comprehensive, easy-to-read pocket book distilling the most clinically up-to-date information on thrombotic and bleeding disorders\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eIn a concise manner, \u003ci\u003eBlombäck’s Essential Guide to Blood Coagulation\u003c\/i\u003e distills the most clinically up-to-date information on thrombotic and bleeding disorders, including the latest treatment strategies for key conditions and diseases. This book covers both the stable and the acute stages of hereditary and acquired bleeding and thrombotic disorders in adults, children, and geriatric patients. It also highlights the laboratory tests that can aid in diagnosing and identifying the cause of bleeding and\/or thrombosis in a patient. \u003c\/p\u003e\u003cp\u003eThe book is organized into four main sections, each featuring numerous updates in this new edition. The first part introduces the reader to laboratory hemostasis and hemostasis physiology. The second part covers bleeding disorders, including a new chapter on bleeding disorders and aging. The third part discusses thromboembolic disorders, with a new chapter on extracorporeal membrane oxygenation (ECMO). The final section addresses special issues in hemostasis, with new chapters on hemostasis in renal disease, liver disorders, and cancer, as well as updated information on thrombotic thrombocytopenic purpura. \u003c\/p\u003e\u003cp\u003eThis edition of \u003ci\u003eBlombäck’s Essential Guide to Blood Coagulation\u003c\/i\u003e also includes updates on: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eHemostasis in COVID-19 and vaccine-induced thrombotic thrombocytopenia (VITT), a rare condition observed during pandemic\u003c\/li\u003e\n\u003cli\u003eCritical bleeding in different clinical situations and hemostasis in obstetrics and gynecology\u003c\/li\u003e\n\u003cli\u003ePlatelet disorders, and rare coagulation factor deficiencies, cerebral vein and splanchnic vein thrombosis\u003c\/li\u003e\n\u003cli\u003eThe greater paradigm shift in the treatment of hereditary bleeding disorders since the last edition was published\u003c\/li\u003e\n\u003cli\u003eLaboratory issues in hemostasis, including nomenclature and sampling\u003c\/li\u003e\n\u003cli\u003eSpecific issues of hemostasis in children\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eCompact enough to fit into a coat pocket, \u003ci\u003eBlombäck’s Essential Guide to Blood Coagulation\u003c\/i\u003e is a valuable guide for all those treating patients to expand their knowledge of hemostatic disorders. This text fills a void for the residents, fellow doctors, and practicing physicians who need rapid access to up-to-date information. \u003c\/p\u003e\u003cp\u003eContributors, xi\u003c\/p\u003e \u003cp\u003ePreface, xiii\u003c\/p\u003e \u003cp\u003eAbbreviations, xv\u003c\/p\u003e \u003cp\u003ePART 1: GENERAL HEMOSTASIS\u003c\/p\u003e \u003cp\u003e1 Overview of normal hemostasis, 3\u003c\/p\u003e \u003cp\u003eJovan P. Antovic, Maria Farm, and Charlotte Gran\u003c\/p\u003e \u003cp\u003e2 Sampling instructions and preanalytical issues in hemostasis, 6\u003c\/p\u003e \u003cp\u003eMaria Farm and Charlotte Gran\u003c\/p\u003e \u003cp\u003ePoints to note prior to blood sampling, 6\u003c\/p\u003e \u003cp\u003eSampling time and patient preparation, 6\u003c\/p\u003e \u003cp\u003eReferrals for coagulation analyses, 7\u003c\/p\u003e \u003cp\u003eSampling, 7\u003c\/p\u003e \u003cp\u003eSample handling, 8\u003c\/p\u003e \u003cp\u003e3 Laboratory investigation, 9\u003c\/p\u003e \u003cp\u003eJovan P. Antovic, Maria Farm, Charlotte Gran, Bianca Tesi, and Agneta Wikman\u003c\/p\u003e \u003cp\u003eNomenclature, 9\u003c\/p\u003e \u003cp\u003eScreening analyses, 9\u003c\/p\u003e \u003cp\u003eSpecial analyses, 16\u003c\/p\u003e \u003cp\u003ePlatelet assays, 24\u003c\/p\u003e \u003cp\u003eGenetic testing, 26\u003c\/p\u003e \u003cp\u003eGlobal hemostatic assays, 28\u003c\/p\u003e \u003cp\u003eUseful assays in research studies, 31\u003c\/p\u003e \u003cp\u003ePART 2: BLEEDING DISORDERS\u003c\/p\u003e \u003cp\u003e4 Clinical and laboratory investigation of increased bleeding tendency, 37\u003c\/p\u003e \u003cp\u003eCharlotte Gran and Maria Magnusson\u003c\/p\u003e \u003cp\u003eIntroduction, 37\u003c\/p\u003e \u003cp\u003eClinical investigation, 37\u003c\/p\u003e \u003cp\u003eLaboratory investigations, 39\u003c\/p\u003e \u003cp\u003eHEREDITARY BLEEDING DISORDERS\u003c\/p\u003e \u003cp\u003e5 Hemophilia, 45\u003c\/p\u003e \u003cp\u003eMargareta Holmström and Susanna Ranta\u003c\/p\u003e \u003cp\u003eIntroduction, 45\u003c\/p\u003e \u003cp\u003eBleeding symptoms in hemophilia, 45\u003c\/p\u003e \u003cp\u003eTreatment, 45\u003c\/p\u003e \u003cp\u003eClinical follow-up of patients with bleeding disorders, 51\u003c\/p\u003e \u003cp\u003e6 Von Willebrand disease, 52\u003c\/p\u003e \u003cp\u003eTony Frisk and Margareta Holmström\u003c\/p\u003e \u003cp\u003eIntroduction, 52\u003c\/p\u003e \u003cp\u003eClassification, 52\u003c\/p\u003e \u003cp\u003eDiagnosis, 52\u003c\/p\u003e \u003cp\u003eManagement, 53\u003c\/p\u003e \u003cp\u003e7 Rare bleeding disorders including inherited platelet function defects, 58\u003c\/p\u003e \u003cp\u003eCecilia Karlström and Maria Magnusson\u003c\/p\u003e \u003cp\u003eInherited platelet function defects, 58\u003c\/p\u003e \u003cp\u003eVery rare coagulation factor deficiencies, 60\u003c\/p\u003e \u003cp\u003eVascular bleeding disorders, 63\u003c\/p\u003e \u003cp\u003eBleeding disorder of unknown cause (BDUC), 64\u003c\/p\u003e \u003cp\u003e8 Specific issues of hemostasis in children – focus on bleeding, 65\u003c\/p\u003e \u003cp\u003eMaria Farm and Susanna Ranta\u003c\/p\u003e \u003cp\u003eDevelopmental hemostasis, 65\u003c\/p\u003e \u003cp\u003eBleeding in children, 65\u003c\/p\u003e \u003cp\u003eCoagulation factor deficiencies, 68\u003c\/p\u003e \u003cp\u003ePlatelet function defects and thrombocytopenia, 69\u003c\/p\u003e \u003cp\u003e9 Hereditary bleeding disorders and aging, 71\u003c\/p\u003e \u003cp\u003eJovan P. Antovic, Roza Chaireti, and Joel Ohm\u003c\/p\u003e \u003cp\u003eCardiovascular disease (CVD), 71\u003c\/p\u003e \u003cp\u003eAtrial fibrillation, 71\u003c\/p\u003e \u003cp\u003eAtherosclerotic cardiovascular disease (ASCVD), 72\u003c\/p\u003e \u003cp\u003eCancer, 73\u003c\/p\u003e \u003cp\u003eChronic kidney disease, 73\u003c\/p\u003e \u003cp\u003e10 Paradigm change – new treatment for hereditary bleeding disorders, 75\u003c\/p\u003e \u003cp\u003eMaria Magnusson and Susanna Ranta\u003c\/p\u003e \u003cp\u003eCoagulation factor concentrates, 75\u003c\/p\u003e \u003cp\u003eNonfactor replacement therapy, 75\u003c\/p\u003e \u003cp\u003eGene therapy, 76\u003c\/p\u003e \u003cp\u003eACQUIRED BLEEDING DISORDERS\u003c\/p\u003e \u003cp\u003e11 Acquired inhibitors of coagulation factors, 81\u003c\/p\u003e \u003cp\u003eRoza Chaireti, Margareta Holmström, and Cecilia Karlström\u003c\/p\u003e \u003cp\u003eAcquired hemophilia, 81\u003c\/p\u003e \u003cp\u003eAcquired von Willebrand disease, 84\u003c\/p\u003e \u003cp\u003eCRITICAL BLEEDINGS\u003c\/p\u003e \u003cp\u003e12 Critical bleeding in trauma and surgery, 89\u003c\/p\u003e \u003cp\u003eAndreas Andersson, Carl Magnus Wahlgren, and Agneta Wikman\u003c\/p\u003e \u003cp\u003eBackground, 89\u003c\/p\u003e \u003cp\u003ePathophysiology, resuscitation, and surgical management of traumatic bleeding, 89\u003c\/p\u003e \u003cp\u003eManagement of acute bleeding in surgery, 91\u003c\/p\u003e \u003cp\u003eTreatment protocols, 91\u003c\/p\u003e \u003cp\u003ePediatric considerations, 92\u003c\/p\u003e \u003cp\u003e13 Gastrointestinal bleeding, 93\u003c\/p\u003e \u003cp\u003eMaria Magnusson and Per Stål\u003c\/p\u003e \u003cp\u003eBackground, 93\u003c\/p\u003e \u003cp\u003eDiagnosis, 93\u003c\/p\u003e \u003cp\u003eAcute management, 94\u003c\/p\u003e \u003cp\u003eDiagnostic-therapeutic procedures, 94\u003c\/p\u003e \u003cp\u003eSecondary prophylaxis after GI bleeding, 95\u003c\/p\u003e \u003cp\u003eConsiderations regarding hemostasis in GI bleeding, 95\u003c\/p\u003e \u003cp\u003e14 Intracranial bleeding, 96\u003c\/p\u003e \u003cp\u003eMichael V. Mazya and Michael Nekludov\u003c\/p\u003e \u003cp\u003eIntracerebral hemorrhage, 96\u003c\/p\u003e \u003cp\u003eSubarachnoid hemorrhage, 98\u003c\/p\u003e \u003cp\u003eTraumatic brain injury, 99\u003c\/p\u003e \u003cp\u003e15 Obstetric massive bleeding, 101\u003c\/p\u003e \u003cp\u003eMaria Sennström\u003c\/p\u003e \u003cp\u003eBackground, 101\u003c\/p\u003e \u003cp\u003eManagement, 101\u003c\/p\u003e \u003cp\u003eSpecific treatments, 101\u003c\/p\u003e \u003cp\u003eFollow-up, 102\u003c\/p\u003e \u003cp\u003e16 Bleedings associated with anticoagulant and antiplatelet treatment\u003c\/p\u003e \u003cp\u003e(including reversal of antithrombotic treatment), 103\u003c\/p\u003e \u003cp\u003eMargareta Holmström and Joel Ohm\u003c\/p\u003e \u003cp\u003eBackground, 103\u003c\/p\u003e \u003cp\u003eManagement, 103\u003c\/p\u003e \u003cp\u003ePART 3: THROMBOEMBOLIC DISORDERS\u003c\/p\u003e \u003cp\u003eVENOUS THROMBOSIS\u003c\/p\u003e \u003cp\u003e17 Venous thromboembolism, 111\u003c\/p\u003e \u003cp\u003eJoel Ohm\u003c\/p\u003e \u003cp\u003eBackground, 111\u003c\/p\u003e \u003cp\u003eRisk factor review, 111\u003c\/p\u003e \u003cp\u003eDiagnosis, 115\u003c\/p\u003e \u003cp\u003eManagement, 117\u003c\/p\u003e \u003cp\u003eFollow-up and secondary prevention, 119\u003c\/p\u003e \u003cp\u003eFurther investigations to consider, 119\u003c\/p\u003e \u003cp\u003eRare underlying causes, 120\u003c\/p\u003e \u003cp\u003eContinued follow-up, 121\u003c\/p\u003e \u003cp\u003e17.1 Cerebral venous thrombosis, 122\u003c\/p\u003e \u003cp\u003eMichael V. Mazya and Joel Ohm\u003c\/p\u003e \u003cp\u003eBackground, 122\u003c\/p\u003e \u003cp\u003eCauses and risk factors, 122\u003c\/p\u003e \u003cp\u003eDiagnosis, 122\u003c\/p\u003e \u003cp\u003eManagement, 123\u003c\/p\u003e \u003cp\u003e17.2 Splanchnic vein thrombosis, 125\u003c\/p\u003e \u003cp\u003eMaria Magnusson and Per Stål\u003c\/p\u003e \u003cp\u003eBackground, 125\u003c\/p\u003e \u003cp\u003eDiagnosis, 125\u003c\/p\u003e \u003cp\u003eManagement, 126\u003c\/p\u003e \u003cp\u003e18 Specific issues of hemostasis in children – focus on thrombosis, 128\u003c\/p\u003e \u003cp\u003eTony Frisk\u003c\/p\u003e \u003cp\u003eBackground, 128\u003c\/p\u003e \u003cp\u003eSymptoms and signs, 129\u003c\/p\u003e \u003cp\u003eDiagnosis, 129\u003c\/p\u003e \u003cp\u003eManagement, 129\u003c\/p\u003e \u003cp\u003eTreatment, 129\u003c\/p\u003e \u003cp\u003eHeparin-induced thrombocytopenia (HIT), 132\u003c\/p\u003e \u003cp\u003ePercutaneous catheter-directed therapies, 132\u003c\/p\u003e \u003cp\u003eSystemic thrombolysis, 132\u003c\/p\u003e \u003cp\u003eCatheter-related thrombosis, 133\u003c\/p\u003e \u003cp\u003eCerebral sinus venous thrombosis, 133\u003c\/p\u003e \u003cp\u003eArterial thrombosis, 133\u003c\/p\u003e \u003cp\u003eArterial ischemic stroke (AIS), 134\u003c\/p\u003e \u003cp\u003e19 Thrombotic issues with artificial surfaces, 135\u003c\/p\u003e \u003cp\u003eLars Mikael Broman and Moa Simonsson\u003c\/p\u003e \u003cp\u003eProsthetic heart valves, 135\u003c\/p\u003e \u003cp\u003eECMO, 137\u003c\/p\u003e \u003cp\u003e20 Treatment and prevention of venous thromboembolism, 142\u003c\/p\u003e \u003cp\u003eMargareta Holmström and Joel Ohm\u003c\/p\u003e \u003cp\u003eAcute phase therapies, 142\u003c\/p\u003e \u003cp\u003ePharmacological maintenance treatment, 146\u003c\/p\u003e \u003cp\u003eNonpharmacological maintenance treatment, 150\u003c\/p\u003e \u003cp\u003ePrimary prevention, 151\u003c\/p\u003e \u003cp\u003e21 Prevention of cardioembolism in atrial fibrillation, 153\u003c\/p\u003e \u003cp\u003eMichael V. Mazya and Moa Simonsson\u003c\/p\u003e \u003cp\u003eBackground, 153\u003c\/p\u003e \u003cp\u003eAssessment of cardioembolic risk, 153\u003c\/p\u003e \u003cp\u003eAssessment of bleeding risk, 153\u003c\/p\u003e \u003cp\u003eClinical implications of risk assessment, 154\u003c\/p\u003e \u003cp\u003eStroke prevention in atrial fibrillation, 154\u003c\/p\u003e \u003cp\u003eCombination therapy (oral anticoagulant + antiplatelet therapy), 155\u003c\/p\u003e \u003cp\u003eCardioversion, 155\u003c\/p\u003e \u003cp\u003eLeft atrial appendix closure, 155\u003c\/p\u003e \u003cp\u003eTiming of OAC initiation after ischemic stroke and TIA, 156\u003c\/p\u003e \u003cp\u003eResuming oral anticoagulation after intracerebral hemorrhage, 156\u003c\/p\u003e \u003cp\u003e22 Laboratory investigation of anticoagulant treatment, 157\u003c\/p\u003e \u003cp\u003eJovan P. Antovic and Maria Farm\u003c\/p\u003e \u003cp\u003eWarfarin (PT [INR]), 157\u003c\/p\u003e \u003cp\u003eDirect oral anticoagulants (anti-factor IIa and anti-factor Xa), 157\u003c\/p\u003e \u003cp\u003eLow molecular weight heparin (anti-factor Xa), 158\u003c\/p\u003e \u003cp\u003eUnfractionated heparin (APTT, anti-factor Xa), 158\u003c\/p\u003e \u003cp\u003eArgatroban (anti-factor IIa\/direct thrombin inhibition, dTT), 159\u003c\/p\u003e \u003cp\u003eARTERIAL THROMBOSIS\u003c\/p\u003e \u003cp\u003e23 Ischemic heart disease, 163\u003c\/p\u003e \u003cp\u003eMoa Simonsson\u003c\/p\u003e \u003cp\u003eBackground, 163\u003c\/p\u003e \u003cp\u003eAcute coronary syndrome (ACS), 163\u003c\/p\u003e \u003cp\u003eChronic coronary syndrome (CCS), 166\u003c\/p\u003e \u003cp\u003e24 Ischemic stroke and transient ischemic attack (TIA), 168\u003c\/p\u003e \u003cp\u003eMichael V. Mazya\u003c\/p\u003e \u003cp\u003eBackground, 168\u003c\/p\u003e \u003cp\u003eCauses and risk factors, 168\u003c\/p\u003e \u003cp\u003eDiagnosis, 168\u003c\/p\u003e \u003cp\u003eManagement, 168\u003c\/p\u003e \u003cp\u003e25 Peripheral artery disease, 173\u003c\/p\u003e \u003cp\u003eCarl Magnus Wahlgren\u003c\/p\u003e \u003cp\u003eBackground, 173\u003c\/p\u003e \u003cp\u003eAntithrombotic therapy for cardiovascular prevention in PAD, 173\u003c\/p\u003e \u003cp\u003ePerioperative antithrombotic therapy in PAD, 174\u003c\/p\u003e \u003cp\u003eAntithrombotic therapy after endovascular intervention for lower extremity artery disease, 174\u003c\/p\u003e \u003cp\u003eAntithrombotic therapy after bypass surgery for lower extremity artery disease, 174\u003c\/p\u003e \u003cp\u003e26 Antiplatelet treatment, 176\u003c\/p\u003e \u003cp\u003eMichael V. Mazya and Moa Simonsson\u003c\/p\u003e \u003cp\u003eBackground, 176\u003c\/p\u003e \u003cp\u003eCyclooxygenase-1 inhibitor, 176\u003c\/p\u003e \u003cp\u003eOral P2Y12 inhibitors, 176\u003c\/p\u003e \u003cp\u003eIntravenous P2Y12 inhibitor, 177\u003c\/p\u003e \u003cp\u003eGlycoprotein IIb\/IIIa blocker, 177\u003c\/p\u003e \u003cp\u003e27 Laboratory investigation of antiplatelet treatment, 178\u003c\/p\u003e \u003cp\u003eCharlotte Gran and Moa Simonsson\u003c\/p\u003e \u003cp\u003eBackground, 178\u003c\/p\u003e \u003cp\u003eVerifyNow, 178\u003c\/p\u003e \u003cp\u003eMultiplate, 179\u003c\/p\u003e \u003cp\u003eOverall limitations of platelet function tests, 180\u003c\/p\u003e \u003cp\u003ePART 4: SPECIAL HEMOSTASIS\u003c\/p\u003e \u003cp\u003e28 Hemostasis in rheumatological and systemic disease, 183\u003c\/p\u003e \u003cp\u003eAleksandra Antovic and Francesca Faustini\u003c\/p\u003e \u003cp\u003eIntroduction, 183\u003c\/p\u003e \u003cp\u003eSpondylarthritis and psoriatic arthritis, 184\u003c\/p\u003e \u003cp\u003eSystemic autoimmune rheumatic diseases, 184\u003c\/p\u003e \u003cp\u003eManagement, 185\u003c\/p\u003e \u003cp\u003eAntiphospholipid syndrome, 186\u003c\/p\u003e \u003cp\u003e29 Hemostasis in COVID-19, 189\u003c\/p\u003e \u003cp\u003eMaria Magnusson and Anna Sjöström\u003c\/p\u003e \u003cp\u003eBackground, 189\u003c\/p\u003e \u003cp\u003eDiagnosis, 190\u003c\/p\u003e \u003cp\u003eManagement, 190\u003c\/p\u003e \u003cp\u003ePediatric aspects including MIS-C, 191\u003c\/p\u003e \u003cp\u003e30 Hemostasis in liver disease, 192\u003c\/p\u003e \u003cp\u003eMaria Magnusson and Per Stål\u003c\/p\u003e \u003cp\u003eBackground, 192\u003c\/p\u003e \u003cp\u003eLaboratory tests, 192\u003c\/p\u003e \u003cp\u003eManagement in special situations, 193\u003c\/p\u003e \u003cp\u003e31 Hemostasis in kidney disease, 195\u003c\/p\u003e \u003cp\u003ePeter Bárány and Maria Magnusson\u003c\/p\u003e \u003cp\u003eBackground, 195\u003c\/p\u003e \u003cp\u003eBleeding in kidney disease, 195\u003c\/p\u003e \u003cp\u003eThrombosis in kidney disease, 197\u003c\/p\u003e \u003cp\u003e32 Hemostasis in obstetrics and gynecology, 199\u003c\/p\u003e \u003cp\u003eRoza Chaireti and Maria Sennström\u003c\/p\u003e \u003cp\u003eHeavy menstrual bleeding, 199\u003c\/p\u003e \u003cp\u003eBleeding disorders in obstetrics, inherited and aquired, 200\u003c\/p\u003e \u003cp\u003eContraception, hormonal replacement therapy, and risk of thrombosis, 204\u003c\/p\u003e \u003cp\u003eThromboprophylaxis in obstetrics, including risk assessment, 206\u003c\/p\u003e \u003cp\u003eThromboembolism in obstetrics including acute management, 214\u003c\/p\u003e \u003cp\u003e33 Hemostasis in cancer, 219\u003c\/p\u003e \u003cp\u003eRoza Chaireti, Tony Frisk, Charlotte Gran, and Susanna Ranta\u003c\/p\u003e \u003cp\u003eCancer-associated thrombosis, 219\u003c\/p\u003e \u003cp\u003eHemostasis in children’s malignancy, 221\u003c\/p\u003e \u003cp\u003e34 Emergency conditions associated with hemostatic abnormalities, 224\u003c\/p\u003e \u003cp\u003eJovan P. Antovic, Margareta Holmström, and Cecilia Karlström\u003c\/p\u003e \u003cp\u003eDisseminated intravascular coagulation, 224\u003c\/p\u003e \u003cp\u003eHeparin-induced thrombocytopenia, 226\u003c\/p\u003e \u003cp\u003eThrombotic microangiopathies, 228\u003c\/p\u003e \u003cp\u003eIndex, 230\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eJovan P. Antovic, MD, PhD,\u003c\/b\u003e Professor in coagulation and clinical chemistry and Senior Consultant, Department of Clinical Chemistry, Karolinska University Hospital and Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet, Stockholm, Sweden. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eMaria Magnusson, MD, PhD,\u003c\/b\u003e Head of the Department of Hematology and Senior Consultant in pediatric and adult coagulation, Karolinska University Hospital. Affiliated researcher, Department of Molecular Medicine \u0026amp; Surgery and Division of Pediatrics, Department of Clinical Science, Intervention \u0026amp; Technology, Karolinska Institutet.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eNew edition of a concise, comprehensive, easy-to-read pocket book distilling the most clinically up-to-date information on thrombotic and bleeding disorders\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eIn a concise manner, \u003ci\u003eBlombäck’s Essential Guide to Blood Coagulation\u003c\/i\u003e distills the most clinically up-to-date information on thrombotic and bleeding disorders, including the latest treatment strategies for key conditions and diseases. This book covers both the stable and the acute stages of hereditary and acquired bleeding and thrombotic disorders in adults, children, and geriatric patients. It also highlights the laboratory tests that can aid in diagnosing and identifying the cause of bleeding and\/or thrombosis in a patient. \u003c\/p\u003e\u003cp\u003eThe book is organized into four main sections, each featuring numerous updates in this new edition. The first part introduces the reader to laboratory hemostasis and hemostasis physiology. The second part covers bleeding disorders, including a new chapter on bleeding disorders and aging. The third part discusses thromboembolic disorders, with a new chapter on extracorporeal membrane oxygenation (ECMO). The final section addresses special issues in hemostasis, with new chapters on hemostasis in renal disease, liver disorders, and cancer, as well as updated information on thrombotic thrombocytopenic purpura. \u003c\/p\u003e\u003cp\u003eThis edition of \u003ci\u003eBlombäck’s Essential Guide to Blood Coagulation\u003c\/i\u003e also includes updates on: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eHemostasis in COVID-19 and vaccine-induced thrombotic thrombocytopenia (VITT), a rare condition observed during pandemic\u003c\/li\u003e\n\u003cli\u003eCritical bleeding in different clinical situations and hemostasis in obstetrics and gynecology\u003c\/li\u003e\n\u003cli\u003ePlatelet disorders, and rare coagulation factor deficiencies, cerebral vein and splanchnic vein thrombosis\u003c\/li\u003e\n\u003cli\u003eThe greater paradigm shift in the treatment of hereditary bleeding disorders since the last edition was published\u003c\/li\u003e\n\u003cli\u003eLaboratory issues in hemostasis, including nomenclature and sampling\u003c\/li\u003e\n\u003cli\u003eSpecific issues of hemostasis in children\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eCompact enough to fit into a coat pocket, \u003ci\u003eBlombäck’s Essential Guide to Blood Coagulation\u003c\/i\u003e is a valuable guide for all those treating patients to expand their knowledge of hemostatic disorders. This text fills a void for the residents, fellow doctors, and practicing physicians who need rapid access to up-to-date information.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988848394469,"sku":"NP9781394223121","price":75.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781394223121.jpg?v=1761781761","url":"https:\/\/k12savings.com\/products\/blombacks-essential-guide-to-blood-coagulation-isbn-9781394223121","provider":"K12savings","version":"1.0","type":"link"}